Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-55

SponsorVertex Pharmaceuticals Incorporated

About this trial

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.

Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m²)

A total body weight of more than (>) 50 kg

Male and Female participants of non-childbearing potential

History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug

Any condition possibly affecting drug absorption

128 Participants

are divided into 4 treatment groups

Vertex Pharmaceuticals Incorporated

Lead sponsor